The deal with the Korean government covers the manufacturing and commercialization of NVX-CoV2373, expanding on a prior technology transfer agreement. Doses will be available to citizens in the Republic of Korea this year, the companies said in a statement.
Novovax's NVX-CoV2373 is a protein-based vaccine candidate developed with the company's proprietary recombinant nanoparticle technology. The liquid product is stable with refrigeration, which the company says eases distribution.
Copyright © 2021 scienceboard.net